Posttherapeutic Intraaxial Brain Tumor: The Value of Perfusion-sensitive Contrast-enhanced MR Imaging for Differentiating Tumor Recurrence from Nonneoplastic Contrast-enhancing Tissue
Takeshi Sugahara
,a,
Yukunori Korogia,
Seiji Tomiguchia,
Yoshinori Shigematsua,
Ichiro Ikushimaa,
Tomohiro Kiraa,
Luxia Lianga,
Yukitaka Ushioa and
Mutsumasa Takahashia
a From the Departments of Radiology (T.S., Y.K., S.T., Y.S., I.I., T.K., L.L., M.T.) and Neurosurgery (Y.U.), Kumamoto University School of Medicine, Japan.
View larger version (83K):
[in a new window]
|
FIG 1. 63-year-old woman with a recurrent anaplastic astrocytoma verified by surgical resection.
A, Contrast-enhanced T1-weighted MR image (690/14/1; section thickness, 5 mm) shows a focally enhancing area (arrow) with a surrounding nonenhancing zone of low intensity and mass effect in the right frontal lobe.
B, Anaplastic astrocytoma appears as an area of hyervascularity (arrow) on rCBV map (normalized rCBV ratio, 4.45).
C, Histologic specimen shows densely accumulated tumor cells (hematoxylin-eosin, original magnification x 200).
| |
View larger version (127K):
[in a new window]
|
FIG 2. 78-year-old man with a recurrent glioblastoma. The diagnosis was determined by the progressively enlarging area of enhancement on serial MR images and by the patient's clinical deterioration.
A, Contrast-enhanced T1-weighted MR image (690/14/1; section thickness, 5 mm) shows inhomogeneous enhancement (arrows) with surrounding nonenhancing zone of low intensity and mass effect in the right temporoparietal lobe.
B, The recurrent tumor is seen as an area of hypovascularity (arrows) on the rCBV map (normalized rCBV ratio, 0.83).
C, 201Tl-SPECT scans show abnormal uptake in the area of recurrent tumor (arrow), consistent with tumor recurrence.
| |
View larger version (69K):
[in a new window]
|
FIG 3. 29-year-old man with radiation necrosis (verified by stereotactic biopsy) who had undergone subtotal tumor resection followed by conventional radiation therapy (60 Gy) and systemic chemotherapy 26 months earlier. Ten months later, tumor recurrence was found, and was treated by subtotal resection and chemotherapy.
A, Contrast-enhanced T1-weighted MR image (690/14/1; section thickness, 5 mm) shows enhanced area (arrow) within surrounding nonenhancing zone of low intensity and mass effect in the left temporal lobe.
B, Radiation necrosis appears as an area of hyovascularity (arrow) on the rCBV map (normalized rCBV ratio, 0.56).
C, Histologic specimen shows avascular areas, consistent with radiation necrosis (hematoxylin-eosin; original magnification x 200).
| |
View larger version (92K):
[in a new window]
|
FIG 4. 49-year-old man without tumor recurrence. The diagnosis was based on the decreasing size of the enhanced area on serial MR images.
A, Contrast-enhanced T1-weighted MR image (690/14/1; section thickness, 5 mm) shows a small focus of enhancement (arrow) within surrounding nonenhancing zone of low intensity and mass effect in the left frontal lobe.
B, Enhanced area appears as a region of hypervascularity (arrows) on the rCBV map (normalized rCBV ratio, 1.79).
| |
View larger version (64K):
[in a new window]
|
FIG 5. 20-year-old woman without tumor recurrence. The diagnosis was based on the disappearance of the enhancing area on serial MR images.
A, Contrast-enhanced T1-weighted MR image (690/14/1; section thickness, 5 mm) shows a small focus of enhancement (arrows) within surrounding nonenhancing zone of low intensity and mass effect in the left frontal lobe.
B, The enhancing area appears mildly hypervascular (arrows) on the rCBV map (normalized rCBV ratio, 1.17). The effects of previous surgery can be seen as susceptibility artifacts in right frontal region (arrowheads).
C, 201Tl-SPECT scan shows no abnormal uptake in the enhancing lesion (arrows), consistent with lack of tumor recurrence.
| |
View larger version (16K):
[in a new window]
|
FIG 6. Relationship between normalized rCBV ratios in patients with tumor recurrence and those with nonneoplastic contrast-enhancing tissue
| |
View larger version (12K):
[in a new window]
|
FIG 7. Relationship between thallium indexes in patients with tumor recurrence and those with nonneoplastic contrast-enhancing tissue
| |
